- Home
- DYNC vs SLGL Comparison
DYNC vs SLGL Comparison
Compare DYNC & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DYNC | SLGL |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | Israel |
| Employees | N/A | 28 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.8M | 254.1M |
| IPO Year | 2024 | 2016 |
Fundamental Metrics
Financial Performance| Metric | DYNC | SLGL |
|---|---|---|
| Price | $10.88 | $77.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 49.4K | 41.1K |
| Earning Date | N/A | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.76 | $20.06 |
| 52 Week High | $10.90 | $97.97 |
Technical Indicators
Market Signals| Indicator | DYNC | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 59.55 | 48.57 |
| Support Level | $10.76 | $67.89 |
| Resistance Level | N/A | $81.18 |
| Average True Range (ATR) | 0.02 | 6.41 |
| MACD | 0.00 | -0.77 |
| Stochastic Oscillator | 57.14 | 44.24 |
Price Performance
Historical ComparisonAbout DYNC Dynamix Corporation Class A Ordinary Shares
Dynamix Corp is a blank check company.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.